Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025158 | 1.00 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5701010 | 0.87 | CA12 (0.55) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL5701011 | 0.87 | CA12 (0.55) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL15984330 | 0.86 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL10045883 | 0.84 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL596259 | 0.84 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL596258 | 0.84 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL25195142 | 0.84 | HDAC3 (0.60) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL28505266 | 0.83 | HDAC2 (0.48) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL27375535 | 0.83 | NMT1 (0.61) | THRBKDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | AVENTIS PHARMA S.A. (FR) | 2005-08-04 | — | — | US | claimed |
| EP-3044216-B1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-23 | — | — | EP | disclosed |
| US-9963439-B2 | Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2018-05-08 | — | — | US | disclosed |
| EP-3044216-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | UNIVERSITY OF MONTANA (US) | 2016-07-14 | — | — | US | disclosed |
| US-9162991-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITY OF OTTAWA (CA) | 2015-10-20 | — | — | US | disclosed |
| WO-2015026990-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROLASE | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2014-01-23 | — | — | US | disclosed |
| US-8614233-B2 | Cinnamoyl inhibitors of transglutaminase | UNIVERSITE DE MONTREAL (CA) | 2013-12-24 | — | — | US | disclosed |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | UNIVERSITE DE MONTREAL (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
| US-6140341-A | FOR TREATING PAIN | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-10-31 | — | — | US | disclosed |
| US-5591769-A | PYRROLIDINE DERIVATIVES; ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| US-5541343-A | ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS | KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5096919-A | Pyrrolylphenyl-substituted hydroxamic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0378991-A1 | Certain pyrrolylphenyl-substituted hydroxamic acid derivatives | CIBA-GEIGY AG (CH) | 1990-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200703-A1 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | CYP2B6, CYP26A1, CYP2A6 | HDAC3 654/4885HDAC1 1137/4885HDAC2 1353/4885 |
| US-20100204280-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | HDAC3 974/4885HDAC1 253/4885HDAC2 431/4885 |
| US-20050171346-A1 | Hexahydropyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and methods of preparation | HEXD, CDK5, CHUK | HDAC3 334/4885HDAC1 518/4885HDAC2 478/4885 |
| US-20140024837-A1 | CINNAMOYL INHIBITORS OF TRANSGLUTAMINASE | TGM2, TGM3, TFPI | HDAC3 1448/4885HDAC1 362/4885HDAC2 529/4885 |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | HDAC3 3060/4885HDAC1 1874/4885HDAC2 2979/4885 |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | HDAC3 528/4885HDAC1 850/4885HDAC2 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.